NASDAQ · Healthcare
Invest in Immunocore stock from India
Indian and foreign residents can buy Immunocore (IMCR) shares directly through Paasa.
By Paasa · Updated
Immunocore at a glance
- Price
- $30.85+$0.21 (0.69%)
- Market cap
- $1.57B
- Day range
- $30.27 – $30.93
- P/E
- -171.10
- Dividend yield
- None
- Volume
- 344.21K
- 1 month
- -15.76%
- 6 months
- +4.79%
- YTD
- -11.12%
- 1 year
- -10.16%
- 5 years
- -16.78%
Immunocore statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $297.6M | $248.0M | $197.4M | $144.2M | $27.0M |
| Gross profit | $291.4M | $242.4M | $196.6M | $138.9M | $27.0M |
| Operating income | −$33.7M | −$56.3M | −$47.2M | −$42.8M | −$129.4M |
| Net income | −$26.4M | −$40.8M | −$43.8M | −$43.5M | −$133.5M |
| Earnings per share | −$0.53 | −$1.02 | −$0.89 | −$0.95 | −$3.13 |
| EBITDA | $387.2K | −$38.5M | −$40.9M | −$38.4M | −$123.6M |
| Total assets | $1.1B | $1.0B | $472.4M | $526.8M | $407.3M |
| Total debt | $436.7M | $432.7M | $66.5M | $81.4M | $86.2M |
| Cash and short-term investments | $864.2M | $820.4M | $350.3M | $402.5M | $321.1M |
| Shareholders' equity | $381.0M | $360.7M | $291.9M | $338.9M | $231.5M |
| Operating cash flow | −$8.0M | $26.1M | $2.3M | −$49.2M | −$143.1M |
| Free cash flow | −$11.2M | $20.9M | −$2.0M | −$51.4M | −$144.5M |
| Capital expenditure | −$3.2M | −$5.2M | −$4.3M | −$2.2M | −$1.4M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| AbCellera Biologics | ABCL | $14.82 | $4.53B |
| Vera Therapeutics | VERA | $32.38 | $2.32B |
| Harmony Biosciences | HRMY | $39.29 | $2.27B |
| Celldex Therapeutics | CLDX | $31.64 | $2.11B |
| Biohaven | BHVN | $13.29 | $2.00B |
| Nuvation Bio | NUVB | $5.62 | $1.95B |
| Xeris Biopharma | XERS | $9.98 | $1.72B |
| MannKind | MNKD | $3.34 | $1.07B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $35.00
- High
- $43.00
- Median
- $39.00
- Consensus
- $39.00
Ratings: 9 buy · 5 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Immunocore from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search IMCR and buy
Find Immunocore by name or by its ticker, IMCR, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Immunocore from India
What Immunocore does
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Immunocore operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Immunocore shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Immunocore share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Immunocore stock from India?
Yes. Indian residents and NRIs can buy Immunocore (IMCR) shares directly through Paasa. Immunocore is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Immunocore share?
No. You can buy part of one Immunocore share and add to your position over time. One share is $30.85, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Immunocore dividends taxed for Indian investors?
Immunocore trades on NASDAQ but is domiciled in United Kingdom, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Immunocore shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Immunocore shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.